News Ex-Kite chiefs' biotech to research 'off-the-shelf' CAR-Ts w... Belldegrun and Chang's Allogene to take over from Pfizer in R&D deal
News Novartis' CAR-T drug needs new payment model, says Express S... Cost of Novartis' revolutionary therapy is obstacle, says CMO.
News Gilead swoops to buy Kite for $12billion Gilead has sealed a deal to acquire cell therapy leader Kite for just under $12 billion.
News Real world data essential for CAR-T therapy success Innovators will need to quantify value to bring costly drugs to market.
News Scottish firm gets EU funding for 'off the shelf' cancer cel... First patients could be treated in 2019.
R&D On genomics, NGS, and doing much more good than bad, with Ma... Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
